
Mirum Pharmaceuticals, Inc.
Company Overview
Overall Headcount Trend
Overall Headcount Trend
Company growth over the last 12 months
Salaries
Community Salary Data
Help build salary transparency at Mirum Pharmaceuticals, Inc.. Share your compensation anonymously.
Reviews
Share Interview Experience
Help others prepare by sharing your interview process, questions asked, and tips.
Rate This Company
Share your experience working here including compensation, culture, and work-life balance.
Jobs

About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLITM (chenodiol) tablets.LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
Company Information
- Company Type
- In-House Team
- Company Size
- Founded
- 2018
- Headquarters
- San Mateo
Why Work at Mirum Pharmaceuticals, Inc.?
Discover what makes Mirum Pharmaceuticals, Inc. a great place to build your marketing career. View salary data, benefits, and employee insights on the other tabs.